ArticleMolecular biology reports2026
Preclinical evaluation of anti-orbital ionic calcium compounds reveals differential Annexin V/PI-Defined cell death profiles in MCF-7 breast cancer cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHormone receptor-positive breast cancer frequently develops resistance to conventional therapies, highlighting the need for novel preclinical approaches targeting calcium homeostasis and metabolic stress. MATERIALS AND
methodsER-positive MCF-7 breast cancer cells were treated with increasing concentrations of fatty acid anti-orbital ionic calcium (AIC-FA) and liquid anti-orbital ionic calcium stealth glucose (AIC-SG) (150-9.125 µg/mL) for 0-72 h. Cell viability was assessed using the MTT assay, and apoptosis and necrosis were analyzed by Annexin V/Propidium Iodide flow cytometry.
resultsBoth AIC-FA and AIC-SG reduced cell viability at 24, 48, and 72 h compared with the control group (p < 0.05), with more pronounced effects observed at later time points. No significant differences were detected at the 0-hour time point. Flow cytometry showed changes in Annexin V/PI-defined cell death populations, with AIC-FA associated with increased early apoptotic-like and necrotic-like populations (p < 0.05), whereas AIC-SG showed a greater tendency toward necrotic-like populations. Both compounds significantly reduced the proportion of live cells (p < 0.05).
conclusionAIC-FA and AIC-SG reduced cell viability in MCF-7 breast cancer cells and were associated with partially different Annexin V/PI-defined cell death profiles. These findings support further investigation of the cytotoxic effects of these compounds in preclinical breast cancer models.
Indexed as
Identifiers
42118333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.